DP 9024
Alternative Names: DP-9024Latest Information Update: 14 Jun 2024
At a glance
- Originator Deciphera Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action EIF-2 kinase modulators; EIF2AK4 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Leukaemia
Most Recent Events
- 11 Jun 2024 Deciphera Pharmaceuticals has been acquired by Ono Pharmaceutical
- 14 Apr 2023 Pharmacodynamics data from preclinical trials in Leukaemia presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 14 Mar 2023 Preclinical trials in Leukaemia in USA (PO), prior to March 2023